钌配合物的抗肿瘤活性研究进展*

本文对钌配合物在抗肿瘤方面的研究情况、水解过程、与DNA和蛋白质的作用情况进行了简要的评述。     

钌配合物断裂DNA及其机理研究

DNA是遗传信息的携带者和基因表达的物质基础,金属配合物与DNA的相互作用研究受到广泛关注,成为生物无机化学的重要研究内容之一.与其他类型金属配合物相比,钌配合物具有良好的热力学稳定性以及丰富的光化学、光物理和氧化还原特性,其作为DNA断裂试剂也引起人们的极大兴趣.以近年一些代表性的研究工作为例,本文对钌配合物在DNA断裂作用机制方面的研究进展进行了综述.     

钌配合物抗肿瘤研究新进展*

钌配合物作为抗癌药物的研究已受到广泛关注,成为无机药物化学的重要研究内容之一。本文简要评述了近年来钌配合物的抗肿瘤活性研究进展,包括作为细胞毒药物的钌配合物设计与筛选、钌配合物以端粒酶、DNA拓扑异构酶及蛋白激酶作为抗肿瘤作用新靶点等。     

手性钌配合物的合成、抗肿瘤活性及其与血清蛋白的相互作用

合成了手性钌配合物Δ, Λ-[Ru(bpy)₂(pyip)]²⁺, 通过元素分析、核磁共振、质谱和CD光谱对配合物进行了表征. 采用MTT法评价了3种异构体对多种肿瘤细胞株的体外抗肿瘤活性以及对正常细胞的毒性. 结果表明, Δ-[Ru(bpy)₂(pyip)]²⁺的抗肿瘤活性明显优于其异构体, 对A375, SW480, MCF-7和A549的半数抑制浓度低于顺铂. 通过荧光光谱法研究了在生理pH条件下, 手性钌配合物与牛血清白蛋白(BSA)之间的结合作用以及荧光猝灭机制. 依据Scatchard方程测定了结合常数和结合位点数, 根据热力学方程讨论了两者间的主要作用力类型. 结果表明, 钌配合物对牛血清白蛋白的荧光猝灭机制为静态猝灭. Δ-1, 1和Λ-1与牛血清白蛋白的结合常数分别为1.16×10⁵, 5.12×10⁴和3.64×10⁴, 结合位点数均为1, 主要作用力类型是静电作用. 钌配合物在体内能够被血清蛋白存储转运且结合时对蛋白构象无影响.     

钌多吡啶配合物与DNA作用及抗肿瘤活性

应用电子吸收光谱、荧光光谱和粘度测定等方法研究钌多吡啶配合物[Ru(phen)2(Hecip)]2(phen=1,10-邻菲啰啉,Hecip=2(9-乙基-9H-咔唑-3-基)-1H-咪唑并[4,5-f][1,10]菲啰啉)与DNA相互作用。结果表明配合物与DNA键合计量比为2∶1,键合常数超过105mol-1.L,配合物以插入方式与DNA结合。运用琼脂糖凝胶电泳实验研究配合物诱导pBR322DNA断裂及断裂机理。体外抗肿瘤活性结果表明配合物能有效抑制肿瘤细胞增殖,进一步研究表明配合物可以将细胞周期阻滞在S期。     

2-甲酰噻吩缩氨基硫脲及其芳基钌配合物的合成、结构与抗癌活性研究

合成了2-甲酰噻吩缩氨基硫脲化合物L1,L2和它们的芳基钌配合物[(η6-p-cymene)RuII(TSC)Cl]Cl(1:TSC=L1,2:TSC=L2),其结构经1H NMR,MS和元素分析确认.通过单晶培养得到了1的晶体,并测定其晶体结构.凝胶电泳实验表明,L1和L2与1和2对pBR322质粒DNA存在不同的作用机理.采用MTT法测定了这些化合物对3种人体肿瘤细胞株(SGC7901,BEL7404和CNE-1)的细胞毒活性.其中化合物1对人鼻咽癌细胞株(CNE-1)的有较好的抑制活性,其IC50值为27.8μmol L-1.     

三价金配合物抗肿瘤活性研究*

三价金配合物具有潜在的抗肿瘤活性,是目前金属药物领域的研究热点。本文按配位原子的不同总结了稳定三价金配合物的结构特征,按其生物活性的构效关系、生物靶点和作用机制综述了三价金配合物抗肿瘤活性研究的最新成果：配体的结构特点以及离去基团对三价金配合物的体外细胞毒性影响较大;介绍了用于检测三价金配合物与可能的生物靶分子之间的相互作用的多种物理和生物学方法,重点关注了相互作用的模式,如嵌入/静电吸引/共价结合等,并解释了三价金配合物抗肿瘤活性的原因。最后提出了一些研究新思路,以期有助于设计得到靶标明确的具有良好药理活性的抗肿瘤药物。     

铑配合物的抗肿瘤活性及其作用机制研究

自从Rosenberg等人发现顺铂具有抗肿瘤活性以来，金属配合物的抗肿瘤活性引起了人们的广泛关注。本文综述了近年来铑配合物抗肿瘤活性的研究进展，并对铑配合物的抗肿瘤机制和构效关系进行了探讨，为进一步寻找高效低毒和抗肿瘤谱广的新药物揭示了可循的途径。     

咔咯及其金属配合物与DNA的作用和抗肿瘤活性

咔咯及其金属配合物与DNA相互作用和它们的抗肿瘤活性研究已成为咔咯大环化学前沿课题之一。本文综述了咔咯及其金属配合物与DNA相互作用和关于这类化合物在抗肿瘤方面的研究进展,系统介绍了咔咯及其金属配合物与DNA结合模式、在氧化剂存在或光照条件下的核酸酶活性、与G-四链体DNA相互作用以及这类化合物抗肿瘤活性。     

抗肿瘤多核铂配合物的研究

多核铂配合物作为非经典铂抗肿瘤药物,其抗肿瘤机制与现有铂类抗肿瘤药物不同,因而在克服现有铂类抗肿瘤药物耐药性方面有着巨大的潜力。本文综述了多核铂类抗肿瘤药物的研究进展,以连接铂原子的桥配体结构的不同,可分为六大类:以烷基二胺及其衍生物为桥的多核铂配合物、以含氮杂环为桥的多核铂配合物、以羧酸根为桥的多核铂配合物、以卤素离子为桥的多核铂配合物、以含硫配体为桥的多核铂配合物及以其他配体为桥的多核铂配合物。本文还介绍了这几类多核铂配合物的抗肿瘤机理及在克服顺铂耐药性机理方面的研究进展。     

靶向抑制拓扑异构酶和端粒酶的钌配合物研究进展

金属配合物抗肿瘤研究,尤其是铂类药物,已取得了相对令人瞩目的成功,但同时也面临着包括耐药性和毒副作用等诸多问题。近年来钌配合物作为新的抗癌药物引起了人们的注意。在非铂系药物中,金钌配合物;拓扑异构酶;G-四链体;端粒酶属钌配合物是最有前途的抗癌药物之一,国际上普遍认为钌和钌的配合物属于低毒性,容易吸收并在体内很快排泄。本文将着重介绍钌配合物与DNA结合后进一步引发的细胞内核酶活性抑制研究,从新的角度来诠释钌配合物的抗肿瘤研究最新进展。     

靶向抑制拓扑异构酶和端粒酶的钌配合物研究进展

金属配合物抗肿瘤研究,尤其是铂类药物,已取得了相对令人瞩目的成功,但同时也面临着包括耐药性和毒副作用等诸多问题。近年来钌配合物作为新的抗癌药物引起了人们的注意。在非铂系药物中,金属钌配合物是最有前途的抗癌药物之一,国际上普遍认为钌和钌的配合物属于低毒性,容易吸收并在体内很快排泄。本文将着重介绍钌配合物与DNA结合后进一步引发的细胞内核酶活性抑制研究,从新的角度来诠释钌配合物的抗肿瘤研究最新进展。     

Inside Cover: Aquation Is a Crucial Activation Step for Anticancer Action of Ruthenium(II) Polypyridyl Complexes to Trigger Cancer Cell Apoptosis (Chem. Asian J. 2/2016)

Aquation has been proposed as crucial chemical action step for ruthenium (Ru) complexes, but its effects on the action mechanisms remain elusive. Herein, we have demonstrated the aquation process of a potent Ru polypyridyl complex (RuBmp=[Ru^II(bmbp)(phen)Cl]ClO₄, bmbp=2,6‐bis(6‐methylbenzimidazol‐2‐yl) pyridine, phen=phenanthroline) with a chloride ligand, and revealed that aquation of RuBmp effectively enhanced its hydrophilicity and cellular uptake, thus significantly increasing its anticancer efficacy. The aquation products (H‐RuBmp=[Ru^II(bmbp)(phen)Cl]ClO₄, [Ru^II(bmbp)(phen)(H₂O)]ClO₄, bmbp) exhibited a much higher apoptosis‐inducing ability than the intact complex, with involvement of caspase activation, mitochondria dysfunction, and interaction with cell membrane death receptors. H‐RuBmp demonstrated a higher interaction potency with the cell membrane and induced higher levels of ROS overproduction in cancer cells to regulate the AKT, MAPK, and p53 signaling pathways. Taken together, this study could provide useful information for fine‐tuning the rational design of next‐generation metal medicines.     

DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands

Ruthenium(II) arene complexes of the general formula [RuCl(η⁶-p-cymene)(diamine)]PF₆ (diamine = 1,2-diaminobenzene (1), 2,3-diaminonaphthalene (2), 9,10-diaminophenanthrene (3), 2,3-diaminophenazine (4), and 1,2-diaminoanthraquinone (5) were synthesized. Chloro/aqua exchange was evaluated experimentally for complexes 1 and 2. The exchange process was investigated theoretically for all complexes, revealing relatively fast exchange with no significant influence from the polycyclic aromatic diamines. The calf thymus DNA (CT-DNA) binding of the complexes increased dramatically upon extending the aromatic component of the diamines, as evaluated by changes in absorption spectra upon titration with different concentrations of CT-DNA. An intercalation binding mode was established for the complexes using the increase in the relative viscosity of the CT-DNA following addition of complexes 1 and 2. Theoretical studies showed strong preference for replacement of water by guanine for all the complexes, and relatively strong Ru–N_guanine bonds. The plane of the aromatic systems can assume angles that support non-classical interactions with the DNA and covalent binding, leading to higher binding affinities. The ruthenium arenes illustrated in this study have promising anticancer activities, with the half maximal inhibitory concentration (IC₅₀) values comparable to or better than cisplatin against three cell lines.     

Medicinal Organometallic Chemistry: Designing Metal Arene Complexes as Anticancer Agents

The field of medicinal inorganic chemistry is rapidly advancing. In particular organometallic complexes have much potential as therapeutic and diagnostic agents. The carbon‐bound and other ligands allow the thermodynamic and kinetic reactivity of the metal ion to be controlled and also provide a scaffold for functionalization. The establishment of structure–activity relationships and elucidation of the speciation of complexes under conditions relevant to drug testing and formulation are crucial for the further development of promising medicinal applications of organometallic complexes. Specific examples involving the design of ruthenium and osmium arene complexes as anticancer agents are discussed.     

Imine‐N‐Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p‐Cymene Anticancer Complexes: A Structure–Activity Relationship Study

A family of novel imine‐N‐heterocyclic carbene ruthenium(II) complexes of the general formula [(η⁶‐p‐cymene)Ru(C^N)Cl]PF₆⁻ (where C^N is an imine‐N‐heterocyclic carbene chelating ligand with varying substituents) have been prepared and characterized. In this imine‐N‐heterocyclic carbene chelating ligand framework, there are three potential sites that can be modified, which distinguishes this class of ligand and provides a body of flexibilities and opportunities to tune the cytotoxicity of these ruthenium(II) complexes. The influence of substituent effects of three tunable domains on the anticancer activity and catalytic ability in converting coenzyme NADH to NAD⁺ is investigated. This family of complexes displays an exceedingly distinct anticancer activity against A549 cancer cells, despite their close structural similarity. Complex 9 shows the highest anticancer activity in this series against A549 cancer cells (IC₅₀=14.36 μm ), with an approximately 1.5‐fold better activity than the clinical platinum drug cisplatin (IC₅₀=21.30 μm ) in A549 cancer cells. Mechanistic studies reveal that complex 9 mediates cell death mainly through cell stress, including cell cycle arrest, inducing apoptosis, increasing intracellular reactive oxygen species (ROS) levels, and depolarization of the mitochondrial membrane potential (MMP). Furthermore, lysosomal damage is also detected by confocal microscopy.     

Oxidation of Alcohols Catalyzed by Ruthenium Complexes with Iodosylbenzene as Oxidant

Five ruthenium complexes such as Phen-Ru-Phen, Phen-Ru-Bipy, Phen-Ru-Quin, Quin-Ru-Quin and Bipy-Ru-Quin (where Phen=l, 10-phenanthroline, Quin=8-hydroxyquinoline, Bipy=2, 2‘-bipyridine) were synthesized and used as catalysts for the oxidation of benzylic and primary aliphatic alcohols with iodosylbenzene as oxidant. The oxidations were carried out at room temperature, affording the corresponding aldehydes and ketones with high selectivity.     

Tetrabutylammonium Salts of Ruthenium(II) Nitroso Complexes

The paper describes synthesis of (nBu₄N)₂[RuNOCl₅](I), (nBu₄N)₂[RuNOCl₄OH](II), (nBu₄N)₂×[RuNOCl₄OH]·6H₂O (III), and (nBu₄N)₂[RuNOCl₅]· 2(nBu₄N)₂[RuNOCl₄(H₂O)]·2H₂O (IV). The complexes were studied by IR spectroscopy and powder Xray and crystal Xray analyses. The structures are built up of [RuNOCl₅]^2- (I, IV), [RuNOCl₄OH]^2- (II, III), and [RuNOCl₄(H₂O)]^- (IV) complex anions, (nBu₄N)⁺ cations, and crystal water molecules (III, IV). The substances are moderately soluble in water; highly soluble in polar organic solvents, such as acetone, ethanol, chloroform, methylene chloride; and almost insoluble in carbon tetrachloride and toluene. Under storage in light, the compounds decompose from the surface; in darkness I and II are stable, whereas III and IV can lose part of the crystal water.